MYMasafumi Yamaguchi

Masafumi Yamaguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masafumi Yamaguchi has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma

    by Asato Hashinokuchi, Keisuke Kosai, Naoki Haratake, Takatoshi Fujishita, Shinichiro Shimamatsu, Takuro Kometani, Toshiaki Kawabata, Ryo Toyozawa, Kenichi Taguchi, Mototsugu Shimokawa, et al.

    Objectives: Spread through air spaces (STAS) is a poor prognostic pathological feature recently included as a histological factor in the ninth edition of the TNM (tumor, node, and metastasis) classification. However, its clinical significance in lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations remains unclear. Here, we aimed to evaluate the clinical significance of STAS according to EGFR mutation status. Methods: We retrospectively reviewed 347 patients with completely resected pathological stage 0–IIIB lung adenocarcinoma who were evaluated for both STAS and EGFR mutations between 2015 and 2022. We investigated the association between clinicopathological features and STAS and analyzed its prognostic relevance based on EGFR mutation status. Results: STAS and EGFR mutations were present in 85 (24.5%) and 178 (51.3%) patients, respectively. In patients with EGFR-mutated lung adenocarcinoma, STAS was significantly more prevalent in those with exon 19 deletions than those with the L858R mutation (P = .012). STAS was significantly markedly associated with poorer recurrence-free and overall survival in patients both with (P < .001 and P < .001, respectively) and without (P = .003 and P = .023, respectively) EGFR mutations. Multivariable analysis revealed that STAS was an independent prognostic factor for recurrence-free and overall survival in patients with EGFR mutations (P < .001 and P = .020, respectively). However, STAS was not an independent predictor in patients without EGFR mutations. Conclusions: STAS is a key pathological feature of lung adenocarcinoma and holds considerable clinical relevance, particularly in EGFR-mutated lung adenocarcinoma.


  • Open Access

    Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC

    by Shinkichi Takamori, Toshio Shimokawa, Atsushi Osoegawa, Miyuki Abe, Yohei Takumi, Shunichi Sugawara, Seiji Niho, Yasushi Goto, Hiroaki Okamoto, Katsuyuki Hotta, et al.

  • Open Access

    Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation

    by Shinkichi Takamori, Takashi Seto, Masafumi Yamaguchi, Fumihiko Kinoshita, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Fumihiro Shoji, Tatsuro Okamoto

    Osimertinib is a standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor gene (EGFR) mutations, but most patients with EGFR-mutant NSCLC develop secondary resistance to osimertinib. Mesenchymal-epithelial transition gene (MET) alterations and oncogene fusions have been identified as the most common mechanisms of resistance to osimertinib. However, MET exon 14 skipping mutation (METex14del) as an acquired resistance to osimertinib has rarely been reported. A non-smoking 76-year-old woman was diagnosed with lung adenocarcinoma in the right lower lobe (cT2bN2M1c [pulmonary and bone metastases], cStage IVB). The primary tumor was submitted to cobas® EGFR Mutation Test v2 (Roche Diagnostics Ltd.), next generation sequencing (Oncomine Comprehensive Assay v3; Thermo Fisher Scientific), the AmoyDx® Essential NGS panel (Amoy Diagnostics, Xiamen, China), all of which were positive for EGFR L858R and de novo T790M. We administered daily osimertinib (80 mg/day), and achieved a partial response. However, after 14.0 months, computed tomography showed progression of the primary tumor and lung metastases. Re-biopsy of the primary tumor was conducted, and the specimen was submitted to Archer®MET companion diagnostic for detection of METex14del. Although the primary tumor was negative for METex14del, the re-biopsy specimen was positive for METex14del. We validated that the biopsy specimen of the primary tumor at diagnosis before osimertinib administration was negative for METex14del using local reverse transcription PCR. We administered daily tepotinib (500 mg/day) to the patient as a further-line treatment, and achieved a partial response (tumor shrinkage rate: 34.5%) after 2.0 months, who responded to tepotinib therapy for 8.0 months. We described a patient with lung adenocarcinoma harboring METex14del as a potential acquired resistance to osimertinib, who responded to subsequent tepotinib therapy. Re-biopsy and re-analysis of genetic profiles should be considered in NSCLC patients who develop osimertinib resistance.


  • Open Access

    Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)

    by Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, Hidetoshi Hayashi, Yuki Sato, Takayasu Kurata, Shunichi Sugawara, Isamu Okamoto, Shunsuke Teraoka, Koichi Azuma, et al.

    Durvalumab (anti-programmed cell death ligand-1) administration after concurrent chemoradiotherapy (cCRT) has improved the survival of patients with unresectable, locally advanced (LA) stage III non-small cell lung cancer (NSCLC). Some patients are unable to complete cCRT and cannot receive immunotherapy due to poor performance status based on adverse events after cCRT. Immunotherapy plays an important role in anti-programmed cell death ligand-1 (PD-L1)-positive advanced NSCLC and is replacing chemotherapy. In addition, radiotherapy and immunotherapy have been reported to have a synergistic effect. This Phase II, multicenter study (DOLPHIN, WJOG11619L, JapicCTI-194840) is designed to assess the efficacy and safety of durvalumab plus concurrent curative radiation therapy for PD-L1-positive unresectable LA-NSCLC without chemotherapy. Unresectable LA stage III NSCLC patients aged 20 years or older with a World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and PD-L1 positivity are enrolled. The patients will receive curative radiation therapy (60 Gy) plus durvalumab 10 mg/kg every 2 weeks (q2w) for up to 12 months until there is evidence of disease progression (PD) or unacceptable toxicity. The primary endpoint is the 12-month progression-free survival rate as assessed by an independent central review. The secondary endpoints are progression-free survival, overall survival, objective response rate, treatment completion rate, and safety. Recruitment began in September 2019.


  • Open Access

    Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status

    by Taichi Matsubara, Takashi Seto, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Tatsuro Okamoto

    Purpose: Anti-programmed death 1 (PD-1) antibodies have emerged as frontline treatments for patients with advanced non-small cell lung cancer (NSCLC) on the basis of global Phase III trials. However, current data regarding responses to anti–PD-1 therapy in older patients with NSCLC or those with poor performance status (PS) are limited. Therefore, we examined the therapeutic effect of anti PD-1 antibody in these patients. Patients: We retrospectively examined consecutive patients treated with anti–PD-1 monotherapy (pembrolizumab or nivolumab) from January 2016 to September 2018. Results: We enrolled 125 patients (median age, 60 years), 80.8% of whom were men. Patients aged ≥ 75 years were considered older patients (n = 15), and those with PS 2– 3 were regarded as having poor PS (n = 11). The objective response and disease control rates were 15.4% and 46.2%, respectively, in older patients and 9.1% and 27.3%, respectively, in those with poor PS. Progression-free survival (PFS) and overall survival (OS) did not significantly differ between older and younger patients. However, poor PS was significantly associated with poor survival. High programmed death ligand 1 (PD-L1) expression in tumor specimens (≥ 50%) was associated with favorable survival in the entire cohort as well as patients with poor PS. Safety analyses demonstrated no significant difference in the occurrence of any adverse event, including grade ≥ 3 adverse events, between patients with poor PS or older age and the remaining patients. Conclusion: Anti–PD-1 therapy had similar efficacy in older and younger patients with NSCLC, whereas survival was significantly worse in patients with poor PS. However, immune checkpoint inhibitors may be considered for patients with poor PS harboring positive PD-L1 expression.


  • Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer

    by Masafumi Yamaguchi, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Satoshi Shiono, Hiroshige Yoshioka, Tadashi Aoki, et al.

    Locally advanced non-small cell lung cancer, especially mediastinal lymph node metastasis-positive stage IIIA-N2 cancer, is a heterogeneous disease state characterized by anatomically locally advanced disease with latent micrometastases. Thus, surgical resection or radiotherapy alone has historically failed to cure this disease. During the last three decades, persistent efforts have been made to develop a suitable treatment modality to overcome these problems using chemotherapy and/or radiotherapy with surgical resection. However, the role of surgical resection remains unclear, and the standard treatment for stage IIIA-N2 disease is concurrent chemoradiotherapy. In general, adjuvant chemotherapy is indicated for completely resected pathological stage IB disease or lymph node metastasis-positive pathological stage II or IIIA disease. Platinum-based doublet cytotoxic chemotherapy is currently the standard regimen. Additionally, post-operative radiotherapy might be indicated for post-operatively proven mediastinal lymph node metastasis; i.e. clinical N0–1 and pathological N2 disease. With the remarkable progression that has recently been made in the field of chemotherapy, such as advances in molecular targeting agents and immune checkpoint inhibitors, the basic policy of chemotherapy has been shifting to personalized treatment based on the individual patient’s oncogene driver mutation status, immune status and other parameters. The same trend is being seen in the treatment of stage IIIA-N2 disease. We should consider the past and upcoming results of several clinical trials to optimize the coming era of personalized treatment.


  • Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis

    by Taichi Matsubara, Masafumi Yamaguchi, Mikako Jinnouchi, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Mototsugu Shimokawa, Takashi Seto, Tatsuro Okamoto

    Background Pneumonitis can be triggered by anti-cancer therapies: cytotoxic chemotherapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors. There are few treatment options for patients who develop such pneumonitis and their treatment including chemotherapy is generally difficult thus would limit patient’s prognosis. In this study, we investigated the clinical course of patients with lung cancer who developed anti-cancer therapy-related pneumonitis. Patients and methods We retrospectively examined data of patients who had developed pneumonitis triggered by anti-cancer agents and required hospitalization from January 2014 to March 2019 and analyzed their subsequent clinical course and prognosis. Results The median age of the 58 study patients was 68 years and 82.8% were men. The median interval between first receiving the responsible agent and drug-induced pneumonitis was 7.4 weeks. Approximately 38% of patients were subsequently able to receive some anti-cancer therapy. The median post-pneumonitis overall survival (OS) from commencement of anti-cancer treatment was 13.2 months. No significant differences were found in survival time between treatment agents. However, patients who received some anticancer therapy after pneumonitis had significantly longer survival times than those did not (HR = 4.11, p = 0.0003) and patients who took longer to develop pneumonitis had a longer survival (HR = 2.28, p = 0.0148). Multivariate analysis revealed that short interval to onset and no post-pneumonitis anticancer therapy were independent predictors of short survival. Conclusion Although patients who developed pneumonitis had relatively short survival times, the interval between initial therapy and pneumonitis had survival impact. Survival can be prolonged by administering further cancer treatment after resolution of pneumonitis.


  • Open Access

    Efficacy and Safety of Carboplatin With Nab-Paclitaxel Versus Docetaxel in Elderly Patients with Squamous-Cell Lung Cancer (CAPITAL): A Randomized, Multicenter, Open-Label, Phase III Trial

    by Yoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, Yoichiro Hamamoto, Akiko Kada, Hiroya Hashimoto, Shinji Atagi, Yuichi Takiguchi, Noriyuki Ebi, Akira Inoue, et al.

    Background: In Japan, docetaxel, a cytotoxic monotherapy, is the standard drug administered to elderly patients with advanced non-small cell lung cancer (NSCLC). Carboplatin plus nab-paclitaxel (nab-PC) demonstrated a high objective response rate (ORR) in patients with squamous histology and was suggested to improve overall survival (OS) for these patients. The CAPITAL trial aimed to assess the safety and efficacy of nab-PC versus docetaxel as first-line therapy for elderly patients with advanced squamous NSCLC. Methods: This multicenter, open-label, phase III, randomized trial was performed at 92 institutions in Japan. Inclusion criteria: 1) advanced squamous NSCLC with no prior systemic chemotherapy, 2) age ≥70 years, and 3) Eastern Cooperative Oncology Group performance status 0 or 1. Patients were randomized 1:1 to nab-PC arm (carboplatin AUC, 6 mg/mL/min plus nab-paclitaxel 100 mg/m2 weekly) or D arm (docetaxel 60 mg/m2) for each 21-day cycle. Findings: The nab-PC arm showed higher OS (hazard ratio [HR]: 0·52; 90%CI: 0·38–0·70; median: 16·9 versus 10·9 months; p = 0·0003), progression-free survival (median: 5·8 versus 4·0 months; HR: 0·42; 95%CI: 0·30–0·58; p < 0·0001), and ORR (66·3 versus 28·0%; p < 0·0001) than the D arm. The most common grade 3 or 4 adverse events were leukopenia (46·3%), neutropenia (63·2%), and anemia (38·9%) in the nab-PC arm, and leukopenia (56·7%), neutropenia (77·3%), and febrile neutropenia (17·5%) in the D arm; ≥ grade 2 sensory peripheral neuropathy was observed in 15 (15·8%) and 1 (1·0%) patient(s) in the nab-PC and D arms, respectively. Serious treatment-related adverse events and deaths occurred in 13 (13·7%) and 11 (11·3%) patients and in 2 and 1 patient(s) in the nab-PC and D arms, respectively. Interpretation: Nab-PC improved OS more than docetaxel and can be used as standard first-line treatment for elderly patients with advanced squamous NSCLC. Clinical Trial Registration Details: This trial was registered with the UMIN Clinical Trials Registry (UMIN000019843) and the Japan Registry of Clinical Trials (jRCTs041180110) and its protocol has been published previously. Funding Information: This study was conducted by the National Hospital Organization Nagoya Medical Center under a funding contract with Taiho Pharmaceutical Co. Ltd., Tokyo, Japan. Declaration of Interests: Y.K. reports grants from Taiho Pharmaceutical, during the conduct of the study; grants and personal fees from MSD, personal fees from AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Boehringer Ingelheim, Ono pharmaceutical, outside the submitted work. S.I. reports grants and personal fees from ONO PHARMACEUTICAL CO., LTD., personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K, Bristol-Myers Squibb K.K., Taiho Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., outside the submitted work. H.S. reports grants from Taiho Pharmaceutical, during the conduct of the study; grants and personal fees from AstraZeneca, MSD K.K, Ono Pharmaceutical, personal fees from Boehringer Ingelheim, Chugai Pharma, from Kyorin, outside the submitted work. A.K. reports grants from Taiho Pharmaceutical Co., Ltd., during the conduct of the study; personal fees from Bayer Yakuhin, Ltd., outside the submitted work. S.A. reports grants from The National Cancer Center Research and Development Fund (26-A-22, 29-A-15, 2020-A-13), Taiho Pharmaceutical Co Ltd, during the conduct of the study; grants and personal fees from AstraZeneca, Ono, Taiho, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, MSD, Eli Lilly, Chugai, Merck, grants and non-financial support from F. Hoffmann-La Roche, personal fees from Hisamitsu, Kyowa Hakko Kirin, Novartis Pharma, Thermo Fisher Scientific, outside the submitted work.YT reports grants and personal fees from Taiho pharmaceutical Co, during the conduct of the study; grants and personal fees from Eli Lilly, Ono pharmaceutical Co, Chugai pharmaceutical Co, MSD, Takeda, grants from Daiichi Sankyo, Kyowa-Hakko Kirin, personal fees from Novartis, Boehringer Ingelheim, AstraZeneca, outside the submitted work. A.I. reports personal fees from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Pfizer, Chugai Pharmaceutical, MSD, Daiichi Sankyo, outside the submitted work. T.K. reports personal fees from AstraZeneca, MSD, Eli Lilly, Chugai, Ono, Bristol Myers, Boehringer Ingelheim, grants from AstraZeneca, MSD, Ono, Eli Lilly, Takeda, outside the submitted work. I.O. reports grants from Boehringer Ingelheim, during the conduct of the study; grants and personal fees from AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, MSD Oncology, Lilly, Bristol-Myers Squibb, Chugai Pharma, grants from Astellas Pharma, Novartis, AbbVie, personal fees from Pfizer, outside the submitted work. M.Y. reports grants and personal fees from Chugai Pharmaceutical, grants from Daiichi Sankyo, MSD, Pfizer Japan, outside the submitted work. M.S. reports grants and personal fees from Taiho Pharmaceutical Co., LTD, Chugai Pharmaceutical Co., LTD, MSD K.K, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly Japan K.K., personal fees from AstraZeneca Co., Ltd, outside the submitted work. T.Y. reports grants and personal fees from Takeda, Chugai, Taiho, Ono, Bayer, personal fees from Boehringer Ingelheim, Pfizer, Sysmex, Gilead Sciences, AstraZeneca, MSD, Sanofi, Otsuka, Kyowa Kirin, grants from Daiichi-Sankyo, Astellas, outside the submitted work. M.A. reports grants from Kyowa Kirin, Co. Ltd., outside the submitted work. K.K. reports grants and personal fees from Ono, Boehringer Ingelheim, personal fees from Chugai, MSD, AstraZeneca, Eli Lilly, Daiichi Sankyo, Bristol Myers Squibb, Kyowa Hakko KIRIN, Taiho, outside the submitted work. M.T. reports grants and personal fees from AstraZeneca, Chugai Pharmaceutical, Covidien Japan, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, personal fees from Bristol-Myers Squibb, Johnson & Johnson, Nippon Kayaku, and grants from KM Biologics, outside the submitted work. TS reports grants and personal fees from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, MSD, Novartis Pharma, Pfizer Japan, Takeda Pharmaceutical, grants from AbbVie, Kissei Pharmaceutical, LOXO Oncology, Merck Biopharma, personal fees from AstraZeneca, Bristol-Myers Squibb, Covidien Japan, Kyowa Hakko Kirin, Mochida Pharmaceutical, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Taiho Pharmaceutical, Thermo Fisher Scientific, Precision Medicine Asia, outside the submitted work. N.Y. reports grants and personal fees from MSD K.K., Chugai Pharmaceutical CO., LTD., ONO PHARMACEUTICAL CO., LTD., DAIICHI SANKYO CO., LTD., TAIHO PHARMACEUTICAL CO., LTD., Takeda Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Boehringer-Ingelheim, Novartis, Pfizer Inc., AstraZeneca, personal fees from Thermo Fisher Scientific, Bristol-Myers Squibb, Life Technologies Japan Ltd., NIPPON KAYAKU, Merk Biopharma, grants from Astellas Pharma Inc., TSUMURA & CO., SHIONOGI Co., Ltd., AbbVie GK., Amgen Inc., KYORIN Pharmaceutical Co., Ltd., Eisai Co., Ltd., TERUMO CORPORATION, Toppan Printing Co., Ltd., TOSOH, outside the submitted work. A.G. reports personal fees from Taiho, Nihon Kayaku, AstraZeneca, Chugai, Ono, Behringer-Ingelheim, outside the submitted work. All other authors declare no competing interests. Ethics Approval Statement: The study was approved by the Clinical Research Ethics Committee of each participating institution and written informed consent was obtained from each patient prior to participation in the study. It was conducted in accordance with the principles of the Declaration of Helsinki, 2013.